Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIAPARK: Microglial Activation in Early Parkinson's Disease
NCT03230526Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Apr 2018
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by CHU de Nantes. Primary endpoint: Coefficient of correlation between level of microglial striatal activation and the dopaminergic denervation kinetics at 24 months. Started Apr 2018; status: active, not recruiting.
Beyond the preview
Go deeper on NCT03230526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230526.